{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:22:07Z","timestamp":1784949727519,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chantal BIYA International Reference Centre for research on HIV\/AIDS prevention and management","award":["PTA 2016"],"award-info":[{"award-number":["PTA 2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3871-0","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T15:44:30Z","timestamp":1552578270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon"],"prefix":"10.1186","volume":"19","author":[{"given":"Desire","family":"Takou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1501-2763","authenticated-orcid":false,"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Teto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubin Joseph","family":"Nanfack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Martin","family":"Sosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Dambaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Salpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Clotaire","family":"Billong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Ntungwen","family":"Fokunang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"3871_CR1","unstructured":"World Health Organization. HIV\/AIDS: data and statistics. Geneva: World Health Organization; 2018 http:\/\/www.who.int\/hiv\/data\/en\/ , (Accessed on 09 January 2018)."},{"key":"3871_CR2","unstructured":"World Health Organization. Global Health sector strategy on HIV, 2016\u20132021. Geneva: World Health Organization; 2017. http:\/\/www.who.int\/hiv\/strategy2016-2021\/en\/ , (Accessed on 09 January 2018)."},{"key":"3871_CR3","volume-title":"Progress report. Global action plan on HIV drug resistance 2017\u20132021","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Progress report. Global action plan on HIV drug resistance 2017\u20132021. Geneva: World Health Organization; 2018. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255883\/9789241512848-eng.pdf?sequence=1 ."},{"issue":"10","key":"3871_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","volume":"11","author":"RL Hamers","year":"2011","unstructured":"Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct;11(10):750\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(11)70149-9 .","journal-title":"Lancet Infect Dis"},{"key":"3871_CR5","doi-asserted-by":"publisher","unstructured":"G\u00fcnthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of theInternational antiviral society-USA panel. Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/ciy463.","DOI":"10.1093\/cid\/ciy463."},{"key":"3871_CR6","unstructured":"World Health Organization. Policy brief. Transition to new antiretrovirals in HIV treatment programs. Geneva: World Health Organization; 2017. http:\/\/www.who.int (Accessed on 09 January 2018)."},{"key":"3871_CR7","unstructured":"Fokam J, Santoro MM, Takou D, et al. Pre-treatment HIV-1 drug resistance and genetic diversity in different regions of Cameroon: the CIRCB country-survey. In: Proceedings of the XXVI international workshop on HIV drug resistance and treatment strategies. Johannesburg. South-Africa, 6-8 November 2017."},{"key":"3871_CR8","unstructured":"World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization; 2017 ( http:\/\/www.who.int\/hiv\/pub\/guidelines\/hivdr-guidelines-2017\/en , accessed 26 June 2018)."},{"key":"3871_CR9","unstructured":"World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Second edition. Geneva: 2016. http:\/\/www.who.int (Accessed on 09 January 2018)."},{"issue":"12","key":"3871_CR10","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1089\/aid.2016.0110","volume":"32","author":"TR Dinesha","year":"2016","unstructured":"Dinesha TR, Gomathi S, Boobalan J, et al. Genotypic HIV-1 drug resistance among patients failing Tenofovir-based first-line HAARTin South India. AIDS Res Hum Retrovir. 2016;32(12):1234\u20136 Epub 2016 Jul 14.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"6","key":"3871_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3851\/IMP2650","volume":"18","author":"D Pillay","year":"2013","unstructured":"Pillay D, Albert J, Bertagnolio S, et al. Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the collaborative HIV and anti-HIV drug resistance network. Antivir Ther. 2013;18(6):831\u20136. https:\/\/doi.org\/10.3851\/IMP2650 .","journal-title":"Antivir Ther"},{"key":"3871_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1611-2","volume":"16","author":"SE Rutstein","year":"2016","unstructured":"Rutstein SE, Hosseinipour MC, Weinberger M, et al. Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm. BMC Infect Dis. 2016;16:280. https:\/\/doi.org\/10.1186\/s12879-016-1611-2 .","journal-title":"BMC Infect Dis"},{"issue":"3","key":"3871_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/AID.2016.0070.","volume":"33","author":"S Sivamalar","year":"2017","unstructured":"Sivamalar S, Dinesha TR, Gomathi S, et al. Accumulation of HIV-1 drug resistance mutations after first-line immunological failure to evaluate the options of recycling NRTI drugs in second-line treatment: a study from SouthI ndia. AIDS Res Hum Retrovir. 2017;33(3):271\u20134. https:\/\/doi.org\/10.1089\/AID.2016.0070.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4","key":"3871_CR14","first-page":"221","volume":"15","author":"RJ Lessells","year":"2013","unstructured":"Lessells RJ, Avalos A, de Oliveira T. Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges. AIDS Rev. 2013;15(4):221\u20139 Review.","journal-title":"AIDS Rev"},{"issue":"10","key":"3871_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109148. eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115079. Magubu, Travor [corrected to Mabugu, Travor].","volume":"9","author":"A Phillips","year":"2014","unstructured":"Phillips A, Cambiano V, Nakagawa F, et al. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One. 2014 Oct 7;9(10):e109148. https:\/\/doi.org\/10.1371\/journal.pone.0109148 . eCollection 2014. Erratum in: PLoS One. 2014;9(12):e115079. Magubu, Travor [corrected to Mabugu, Travor].","journal-title":"PLoS One"},{"key":"3871_CR16","unstructured":"Harrison L, La Rosa A, Viana RV et al. Is resistance testing of value after first-line art failure in resource-limited settings? - insights from ACTG 5273. Proceedings of the XXV international workshop on HIV drug resistance and treatment strategies, Boston, Massachusetts, USA, February 20\u201321, 2016."},{"issue":"8","key":"3871_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072680","volume":"8","author":"SC Billong","year":"2013","unstructured":"Billong SC, Fokam J, Aghokeng AF, et al. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. PLoS One. 2013;8(8):e72680.","journal-title":"PLoS One"},{"key":"3871_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2458-13-308","volume":"13","author":"J Fokam","year":"2013","unstructured":"Fokam J, Billong SC, Bissek AC, et al. Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings. BMC Public Health. 2013;13:308.","journal-title":"BMC Public Health"},{"issue":"7","key":"3871_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00705-011-0982-3","volume":"156","author":"R Fokam Salpini","year":"2011","unstructured":"Fokam Salpini R, Santoro MM, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011;156(7):1235\u201343.","journal-title":"Arch Virol"},{"key":"3871_CR20","unstructured":"Technologies, L., SeqScape Software 3.https : \/\/ tools.thermofisher.com \/ content \/ sfs \/ manuals \/ 4474242A.pdf, 2012."},{"issue":"22","key":"3871_CR21","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","volume":"22","author":"JD Thompson","year":"1994","unstructured":"Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673\u201380.","journal-title":"Nucleic Acids Res"},{"key":"3871_CR22","first-page":"60","volume":"2","author":"T Hall","year":"2011","unstructured":"Hall T. Bioedit: an important software for molecular biology. GERF Bull Biosci. 2011;2:60\u20131.","journal-title":"GERF Bull Biosci"},{"key":"3871_CR23","unstructured":"LANL., Consensus Maker. .http : \/\/ www.hiv.lanl.gov \/ content \/ sequence \/ CONSENSUS \/ consensus.html 2015."},{"key":"3871_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/molbev\/msj030","volume":"23","author":"DH Huson","year":"2006","unstructured":"Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol. 2006;23:254\u201367.","journal-title":"Mol Biol Evol"},{"issue":"11","key":"3871_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000581","volume":"5","author":"SL Kosakovsky Pond","year":"2009","unstructured":"Kosakovsky Pond SL, et al. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 2009;5(11):e1000581.","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"3871_CR26","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/nar\/gku739","volume":"42","author":"D Struck","year":"2014","unstructured":"Struck D, et al. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18):e144.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3871_CR27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/JVI.73.1.152-160.1999","volume":"73","author":"KS Lole","year":"1999","unstructured":"Lole KS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73(1):152\u201360.","journal-title":"J Virol"},{"key":"3871_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","volume":"19","author":"AC Pineda-Pena","year":"2013","unstructured":"Pineda-Pena AC, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337\u201348.","journal-title":"Infect Genet Evol"},{"issue":"11","key":"3871_CR29","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608\u201318 Epub 2006 Apr 28.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3871_CR30","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/v6093535","volume":"6","author":"JAF Kamalendra Singh","year":"2014","unstructured":"Kamalendra Singh JAF, Kirby KA, Neogi U, Sonnerborg A, Hachiya A, Das K, Arnold E, McArthur C, Parniak M, Sarafianos SG. Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. Viruses. 2014;6(9):3535\u201362.","journal-title":"Viruses"},{"issue":"12","key":"3871_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1097\/INF.0b013e31822db54c","volume":"30","author":"J Fokam","year":"2011","unstructured":"Fokam J, Salpini R, Santoro MM, et al. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon. Pediatr Infect Dis J. 2011a;30(12):1062\u20138. https:\/\/doi.org\/10.1097\/INF.0b013e31822db54c .","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"3871_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/jmv.23244","volume":"84","author":"L Ceccarelli","year":"2012","unstructured":"Ceccarelli L, Salpini R, Moudourou S, et al. Characterization of drug resistance mutations in na\u00efve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. J Med Virol. 2012 May;84(5):721\u20137.","journal-title":"J Med Virol"},{"key":"3871_CR33","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18004","volume":"16","author":"AF Aghokeng","year":"2013","unstructured":"Aghokeng AF, Kouanfack C, Eymard-Duvernay S, et al. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months\u2019 antiretroviral therapy experience in Cameroon. J Int AIDS Soc. 2013;16:18004. https:\/\/doi.org\/10.7448\/IAS.16.1.18004 .","journal-title":"J Int AIDS Soc"},{"key":"3871_CR34","doi-asserted-by":"publisher","unstructured":"Kuritzkes DR, Bassett RL, et al. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or Stavudine-based regimens. J Acquir Immune Defic Syndr. 2004;36. https:\/\/doi.org\/10.1097\/00126334-200405010-00008 .","DOI":"10.1097\/00126334-200405010-00008"},{"key":"3871_CR35","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organisation","year":"2013","unstructured":"World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organisation; 2013. Available from: http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/"},{"issue":"3","key":"3871_CR36","first-page":"69","volume":"7","author":"AD Luber","year":"2005","unstructured":"Luber AD. Genetic barriers to resistance and impact on clinical response. MedGenMed. 2005;7(3):69.","journal-title":"MedGenMed"},{"issue":"2","key":"3871_CR37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","volume":"11","author":"KL White","year":"2006","unstructured":"White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther. 2006;11(2):155\u201363.","journal-title":"Antivir Ther"},{"issue":"12","key":"3871_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1096\/fasebj.13.12.1511","volume":"13","author":"JY Feng","year":"1999","unstructured":"Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (\u2212)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 1999;13(12):1511\u20137.","journal-title":"FASEB J"},{"key":"3871_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1310\/hct1202-61","volume":"12","author":"DJ McColl","year":"2011","unstructured":"McColl DJ, Margot N, Chen SS, et al. Reduced emergence of the M184V\/I resistance mutation when antiretroviral- naive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials. 2011;12:61\u201370.","journal-title":"HIV Clin Trials"},{"key":"3871_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/cid\/cir1034","volume":"54","author":"MW Tang","year":"2012","unstructured":"Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis. 2012;54:862\u201375.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3871_CR41","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1128\/JCM.00634-17","volume":"55","author":"AJ Nanfack","year":"2017","unstructured":"Nanfack AJ, Redd AD, Bimela JS, et al. Multimethod longitudinal HIV drug resistance analysis in antiretroviral-therapy-naive patients. J Clin Microbiol. 2017;55(9):2785\u2013800.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"3871_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jmv.23846","volume":"86","author":"L Agyingi","year":"2014","unstructured":"Agyingi L, Mayr LM, Kinge T, et al. The evolution of HIV-1 group M genetic variability in southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. J Med Virol. 2014;86(3):385\u201393.","journal-title":"J Med Virol"},{"issue":"4","key":"3871_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/aid.2015.0065","volume":"32","author":"J Fokam","year":"2016","unstructured":"Fokam J, Takou D, Santoro MM, et al. Short communication: population-based surveillance of HIV-1 drug resistance in Cameroonian adults initiating antiretroviral therapy according to the World Health Organization guidelines. AIDS Res Hum Retrovir. 2016;32(4):329\u201333.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"4","key":"3871_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/aid.2015.0286","volume":"32","author":"CR Courtney","year":"2016","unstructured":"Courtney CR, Agyingi L, Fokou A, et al. Monitoring HIV-1 group M subtypes in Yaounde, Cameroon reveals broad genetic diversity and a novel CRF02_AG\/F2 infection. AIDS Res Hum Retrovir. 2016;32(4):381\u20135.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"3871_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14095-4.","volume":"7","author":"G Teto","year":"2017","unstructured":"Teto G, Tagny CT, Mbanya D, et al. Gag P2\/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaound\u00e9, Cameroon. Sci Rep. 2017 Oct 26;7(1):14136. https:\/\/doi.org\/10.1038\/s41598-017-14095-4.","journal-title":"Sci Rep"},{"key":"3871_CR46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.meegid.2016.05.017","volume":"46","author":"D Mir","year":"2016","unstructured":"Mir D, Jung M, Delatorre E, et al. Phylodynamics of the major HIV-1 CRF02_AG African lineages and its global dissemination. Infect Genet Evol. 2016 Dec;46:190\u20139. https:\/\/doi.org\/10.1016\/j.meegid.2016.05.017 .","journal-title":"Infect Genet Evol"},{"issue":"8","key":"3871_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1089\/aid.2015.0225","volume":"32","author":"J Manasa","year":"2016","unstructured":"Manasa J, Danaviah S, Lessells R, et al. Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal, South Africa. AIDS Res Hum Retrovir. 2016;32(8):763\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"2","key":"3871_CR48","first-page":"265","volume":"21","author":"MDM Miller","year":"2007","unstructured":"Miller MDM, Damian MC, Cheng AK. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS Res Hum Retrovir. 2007;21(2):265\u20136.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"9","key":"3871_CR49","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1086\/340130","volume":"185","author":"P Kaleebu","year":"2002","unstructured":"Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes a and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 2002;185(9):1244\u201350.","journal-title":"J Infect Dis"},{"issue":"13","key":"3871_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010176.","volume":"97","author":"J Fokam","year":"2018","unstructured":"Fokam J, Bellocchi MC, Armenia D, et al. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. Medicine. 2018;97(13):e0176. https:\/\/doi.org\/10.1097\/MD.0000000000010176.","journal-title":"Medicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3871-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T20:36:41Z","timestamp":1663101401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3871"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3871-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"24 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical clearance was obtained from the Ethics Review and Consultancy Committee of the Cameroon Bioethics Initiative (Reference number: CBI\/2013\/0139\/ERCC\/CAMBIN), and written informed consent was provided. For those participants under 16\u2009years of age, a written proxy-informed consent was provided to the study coordinators by the respective parent(s) or legal guardian(s), followed by an assent provided by the corresponding participant. Data were de-identified for purpose of confidentiality and privacy in data management.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"246"}}